Varenicline treatment for smoking cessation in high risk patients: a budget impact analysis
نویسندگان
چکیده
منابع مشابه
Varenicline: for smoking cessation.
Varenicline, a partial agonist of alpha4beta2 nicotinic acetylcholine receptor (nAChR), is the most recently approved drug for smoking cessation. Despite the availability of effective treatments for smoking cessation, such as nicotine replacement therapy and Bupropion sustained-release, abstinence rates remain less than optimal. As a nAChR partial agonist, Varenicline attenuates the craving and...
متن کاملOral varenicline for smoking cessation.
OBJECTIVE To review the pharmacology, pharmacokinetics, efficacy, and safety of varenicline and provide a review of relevant clinical data. DATA SOURCES A MEDLINE search (2001-December 2006) was conducted using the key words varenicline and nicotine replacement therapy for clinical trials limited to human subjects and published in English. STUDY SELECTION AND DATA EXTRACTION All available h...
متن کاملVarenicline: a novel pharmacotherapy for smoking cessation.
Varenicline is an orally administered small molecule with partial agonist activity at the alpha4beta2 nicotinic acetylcholine receptor. Varenicline was approved by both the US FDA and the European Medicines Agency of the EU in 2006 as an aid to smoking cessation. Subsequently, varenicline has been approved in over 80 other countries. Varenicline is almost entirely absorbed following oral admini...
متن کاملVarenicline for smoking cessation in patients with coronary heart disease.
Cardiovascular diseases are the leading cause of death in Western countries, and cigarette smoking has a clear causeand-effect relationship with atherosclerotic disease,2,3 with the risk of myocardial infarction (MI) increasing with the number of cigarettes smoked.4 Similarly strong evidence indicates that smoking cessation alone can result in a 36% reduction in the crude relative risk of morta...
متن کاملVarenicline for smoking cessation: efficacy, safety, and treatment recommendations
Smoking is the leading preventable cause of morbidity and mortality in the US, and decreasing smoking prevalence is a public health priority. Patients achieve the greatest success when quit attempts involve behavioral therapy combined with pharmacotherapy. Varenicline is the most recent addition to the pharmacotherapeutic armamentarium for the treatment of tobacco dependence. Varenicline is eff...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Farmeconomia. Health economics and therapeutic pathways
سال: 2017
ISSN: 2240-256X
DOI: 10.7175/fe.v18i1.1331